Abstract
Background Type 1 diabetes (T1D) is a growing public health concern in low-and middle-income countries, where access to glucose monitoring and consistent routine care remains limited. Continuous glucose monitoring (CGM) may improve diabetes outcomes, but evidence of its acceptability and use in low-resource settings is limited. This study explored the perceptions and experiences of CGM use among people living with T1D, their caregivers, and healthcare providers (HCPs).
Methods Participants were recruited from the ACCEDE-U study, a usability study on CGM use among people living with T1D attending a tertiary referral hospital in Nairobi, Kenya. Among 40 participants in the ACCEDE-U study, those who had completed at least seven weeks of CGM use were eligible to participate in the qualitative component. Three focus group discussions (FGDs) were conducted: one with nine caregivers, one with nine adolescents (12-17 years), and one with six young adults (18-24 years). Semi-structured interviews were conducted with 9 HCPs. Data was collected using guides, audio-recorded, transcribed, and analyzed thematically guided by the socioecological framework. CORE-Q guidelines were used to report results.
Results Participants reported increased engagement in glucose monitoring and high acceptability of CGM. Reduced finger-prick testing and real-time alerts were key benefits, particularly among adolescents and young adults, who valued its discreetness and convenience. CGM was perceived to facilitate sharing of glucose data with HCPs. Caregivers reported a reduced monitoring burden. HCPs perceived CGM as valuable for clinical decision-making by providing real-time insights into glycemic patterns. Cost and limited device availability were identified as major barriers to sustained use.
Conclusion CGM was well accepted and perceived as beneficial. However, challenges related to cost and access may limit broader uptake. Improving affordability and availability could enhance feasibility and promote wider implementation in similar settings.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee (P291/03/2025).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The qualitative data generated and analyzed during this study are not publicly available because they contain potentially identifiable participant information. De-identified data are available upon reasonable request.
Funder Information Declared
